Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Inhibrx Biosciences, Inc. (INBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: INBX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 45.87% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 220.18M USD | Price to earnings Ratio 0.13 | 1Y Target Price 12 |
Price to earnings Ratio 0.13 | 1Y Target Price 12 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 |
52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 119.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 861485.5% | Operating Margin (TTM) -116231.5% |
Management Effectiveness
Return on Assets (TTM) -107.28% | Return on Equity (TTM) 41.18% |
Valuation
Trailing PE 0.13 | Forward PE - | Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 |
Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 | ||
Enterprise Value to Revenue 550.94 | Enterprise Value to EBITDA 0.06 | Shares Outstanding 14475900 | Shares Floating 7712906 |
Shares Outstanding 14475900 | Shares Floating 7712906 | ||
Percent Insiders 27.19 | Percent Institutions 68.12 |
Upturn AI SWOT
Inhibrx Biosciences, Inc.
Company Overview
History and Background
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel biologic therapeutic candidates. Founded in 2010, Inhibrx has built a proprietary protein engineering platform to create differentiated antibody-based therapies.
Core Business Areas
- Oncology: Inhibrx develops therapies targeting cancer, focusing on receptor tyrosine kinases and other immune targets.
- Autoimmune and Inflammatory Diseases: Inhibrx has programs aimed at treating autoimmune and inflammatory conditions through modulation of the immune system.
Leadership and Structure
The leadership team includes individuals with extensive experience in drug development and the biotechnology industry. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- INBRX-101: A human recombinant protein designed to bind and neutralize the pro-inflammatory cytokine IL-12. Currently in clinical trials. Competitors include companies developing similar IL-12 inhibitors, like AbbVie (ABBV) and Bristol-Myers Squibb (BMY).
- INBRX-109: A tetravalent agonist antibody designed to activate the PD-1 receptor. Currently in clinical trials. Competitors include companies developing PD-1 agonists, such as Eli Lilly (LLY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for biologics is growing rapidly.
Positioning
Inhibrx is positioned as an innovative biopharmaceutical company focused on developing differentiated therapies. Its competitive advantage lies in its proprietary protein engineering platform.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune disease therapeutics is substantial, projected to be hundreds of billions of dollars. Inhibrx targets specific segments within these markets with unmet medical needs.
Upturn SWOT Analysis
Strengths
- Proprietary protein engineering platform
- Pipeline of novel biologic therapeutic candidates
- Experienced leadership team
- Focus on differentiated therapies
Weaknesses
- Limited resources compared to larger pharmaceutical companies
- Clinical trial risk
- Reliance on external funding
Opportunities
- Potential for strategic collaborations and partnerships
- Expansion of pipeline through internal research and development
- Regulatory approvals for lead product candidates
- Acquisition by a larger pharmaceutical company
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Changes in regulatory landscape
- Economic downturn affecting access to capital
Competitors and Market Share
Key Competitors
- ABBV
- BMY
- LLY
- MRK
- NVS
Competitive Landscape
Inhibrx faces competition from larger, well-established pharmaceutical companies. It must differentiate itself through innovative technologies and targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progress of its pipeline and the expansion of its research programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals.
Recent Initiatives: Recent initiatives include advancing lead product candidates through clinical trials and expanding research efforts into new therapeutic areas.
Summary
Inhibrx Biosciences is a clinical-stage biopharmaceutical company with a promising protein engineering platform. It is in early development and its future hinges on clinical trials. Larger pharmaceutical companies represent significant competition in the oncology and autoimmune disease space and this threat needs to be carefully managed. Current strategy focuses on expanding pipeline candidates which is very risky but offers a large potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Inhibrx Biosciences, Inc. company website
- SEC filings
- Market reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Investing in biopharmaceutical companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibrx Biosciences, Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2024-05-29 | Founder, CEO & Chairman Mr. Mark Paul Lappe | ||
Sector Healthcare | Industry Biotechnology | Full time employees 156 | Website https://inhibrx.com |
Full time employees 156 | Website https://inhibrx.com | ||
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.